GeoVax Labs, Inc. — Q3 2013 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2013. GeoVax is a development-stage biotechnology company developing HIV vaccines; its candidates were in human clinical trials, with no product approvals or commercial product revenue. Grant revenue reflects NIH funding recognized as related costs are incurred.
Financial highlights
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Grant revenue | $1.004 million | $638,000 | $2.243 million | $2.198 million |
| Research and development expense | $879,104 | $601,690 | $2.314 million | $2.386 million |
| General and administrative expense | $316,452 | $334,166 | $1.345 million | $1.339 million |
| Net loss | $190,148 | $296,779 | $1.413 million | $1.525 million |
| Net loss per common share | $0.01 | $0.02 | $0.07 | $0.09 |
| Operating cash used | — | — | $872,040 | $1.893 million |
- At September 30, cash and cash equivalents were $1.721 million, compared with $1.036 million at year-end 2012. Working capital was $1.568 million, versus $1.017 million.
- Total assets were $1.961 million and current liabilities were $225,530. The filing reports no long-term debt or committed credit line.
- Nine-month financing cash flow was $1.643 million, primarily from exercises of 2.933 million warrants. Capital expenditures were $86,602.
- Gross margin is not a meaningful product-performance measure here: revenue consisted of grants, and the filing does not present product sales or a gross-profit line.
Material changes and notable items
- Q3 grant revenue rose year over year, while the nine-month increase was modest. Nine-month R&D expense declined; Q3 R&D expense increased. Net loss narrowed in both comparison periods.
- 2013 G&A included $238,169 of expense from repricing and extending Series B warrants. The related warrant exercises generated $1.643 million in proceeds during the first nine months.
- Common shares outstanding increased to 21,666,610 at September 30 from 18,733,277 at December 31, 2012. The filing also reports a subsequent October 22 issuance of 50,000 shares for consulting services; shares outstanding as of November 12 were 21,716,610.
- Available NIH grant funding was approximately $1.022 million at September 30: about $773,000 from the IPCAVD award and $249,000 from a new SBIR award. The separate $1.9 million clade C grant had been fully used.
Outlook, risks and contingencies
- Management expected cash, working capital and remaining grant funds to support planned operations into the second quarter of 2014, and anticipated raising additional capital during 2013 or early 2014. There is no assurance funding will be available on acceptable terms or at all; a shortfall could force the company to scale back or terminate operations, or seek a merger or acquisition.
- Management expected ongoing losses and higher development costs as programs advance. The company had an accumulated deficit of $26.2 million and no approved products; meaningful product revenue may be years away, if achieved at all.
- A Phase 2a trial of the second-generation preventive vaccine was expected to begin in 2014, potentially enrolling approximately 240 patients. NIH/HVTN support and trial design were not assured. GeoVax-funded Phase 1 therapeutic vaccine trial was expected to be completed in 2013.
- IMPAACT informed GeoVax it could not support a proposed therapeutic-vaccine trial because of resource constraints; the company planned to seek other funding. Risks also include clinical failure, toxicity, regulatory delays, difficulty obtaining grants or capital, and uncertain trial costs and timing.
- Lease payments were $31,760 for the remainder of 2013 and $128,920 in 2014; outstanding unrecorded purchase commitments were approximately $59,985. No legal proceedings were reported. Management said disclosure controls were effective and there were no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether additional financing or grant support was secured before the stated Q2 2014 cash runway expired.
- Actual clinical-trial progress, costs, funding commitments and results, especially the planned preventive-vaccine Phase 2a trial and the company-funded therapeutic trial.
- Remaining grant availability and how grant-related spending and revenue recognition evolve.
- Warrant exercises, share issuance and potential dilution from approximately 8.3 million outstanding warrants and other reserved shares.
- Subsequent developments after September 30, including the 50,000-share consulting issuance and October 2013 employment-agreement amendments.